Pancreatic cancer combo trial halted after just one patient
NCT ID NCT06069778
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study aimed to see if adding the experimental drug BNT321 to standard chemotherapy (mFOLFIRINOX) could help prevent pancreatic cancer from coming back after surgery. It was designed for people whose tumors were completely removed. However, the trial was stopped early after enrolling only one person, so no conclusions can be drawn about safety or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of South Carolina (MUSC)
Charleston, South Carolina, 29425, United States
-
Valkyrie Clinical Trials
Los Angeles, California, 90067, United States
Conditions
Explore the condition pages connected to this study.